# Tracheostomy in Infants in an Australian Tertiary Children's Hospital: Have the Indications and Outcomes Changed?

Katryna Pham MD<sup>1</sup>, Emma Ho<sup>2</sup> MD, Beckie Petulla<sup>3</sup> RN, Ju-lee Oei<sup>1,4</sup> MBBS MD FRACP, Hari Ravindranathan<sup>1,5</sup> MD FCICM, Marlene Soma<sup>1,2</sup> MBBS FRACS

- School of Clinical Medicine, Women's Health, Paediatrics & Children's Health, University of New South Wales, Randwick, NSW 2031, Australia
- Department of Paediatric Otolaryngology, Sydney Children's Hospital, Randwick, NSW 2031, Australia
- Complex and Artificial Airways Clinical Nurse Consultant, Sydney Children's Hospital, Randwick, NSW 2031, Australia
- Department of Newborn Care, Royal Hospital for Women, Randwick, NSW
   2031, Australia
- Paediatric Intensive Care Unit, Sydney Children's Hospital, High Street, Randwick, NSW 2031, Australia

#### **Corresponding author:**

Dr Marlene Soma

Department of Otolaryngology,

Sydney Children's Hospital

High St, Randwick NSW 2031 Australia

Fax: +61 (2) 9326-1932

marlene.soma@health.nsw.gov.au

This study was accepted as a poster presentation at the 72<sup>nd</sup> Australian Society of

Otolaryngology Head Neck Surgery Annual Scientific Meeting in Adelaide, Australia

10<sup>th</sup>-12<sup>th</sup> June 2022

Abstract

Objectives: To determine if there are changes over time for indications and

outcomes of tracheostomies in infants

Methods: Retrospective review of infant tracheostomies at a tertiary children's hospital

across two time periods (Epoch 1: 1997-2008, Epoch 2: 2009-2020). Patient

demographics, tracheostomy indications, comorbidities, length of stay, complications,

decannulation and mortality were examined.

Results: 72 infants had a tracheostomy (40 vs. 32). Airway obstruction decreased

(80% vs. 50%\*) and long-term ventilation increased as the primary indication (17.5%

vs. 40.6%\*). Early complications decreased between the time periods (30% vs.

6.3%\*). The median hospital length of stay was 97 days (IQR 53-205.5), total

complication rate was 53%, decannulation rate was 61% and mortality rate was 17%

(all non-tracheostomy related) across both time periods. There were no significant

changes for these outcomes. \*p<0.05.

Conclusion: Long-term ventilation has increased, and airway obstruction has

decreased as the primary indication for infant tracheostomy over time.

**Key Words:** tracheostomy, infant, airway obstruction, paediatric, ventilation

2

#### Introduction

Tracheostomy insertion may be considered in infants who require bypass of an upper airway obstruction, prolonged ventilatory support or management of excess secretions<sup>1</sup>. Compared to endotracheal intubation, a tracheostomy may allow for discharge from the intensive care setting, and over time, promote the ability to vocalise, mobilise, eat and drink. Depending on the indication and improvement of the underlying condition, a tracheostomy may be reversed through the process of decannulation<sup>2, 3</sup>.

Despite clear improvements for the infant's quality of life and development, tracheostomy placement places an immense economic and care burden on families and the health system. Infants with tracheostomies experience long and costly hospitalisations<sup>4, 5</sup>. Parents and carers must have proficient skills in tracheostomy care, vigilance to tracheostomy tube patency and the ability to manage emergencies including tube dislodgement and obstruction<sup>6, 7</sup>. This has significant impact on psychological wellbeing of families<sup>8, 9</sup>.

Advancements in medical practice have influenced the indications for paediatric tracheostomy particularly with regards to bypassing upper airway obstruction <sup>10</sup>. Prior to the introduction of vaccinations, steroids and antibiotics, a tracheostomy was primarily indicated for acute inflammatory conditions such as laryngotracheobronchitis and diphtheria<sup>6, 11-14</sup>. Over the last two decades, neonatal resuscitation and delivery of airway pressure support with non-invasive ventilation (NIV) has become the preferred modality of respiratory support over intubation <sup>15, 16</sup>. NIV mitigates the risk of iatrogenic airway injury from an endotracheal tube contributing to upper airway obstruction.

Published literature on the indications and outcomes of tracheostomy in infants is heterogeneous across different health systems, countries and timeframes <sup>17-21</sup>. This makes it difficult to ascertain trends reflecting local medical practices.

Approximately half of all paediatric tracheostomies are performed in infants under 1 year of age<sup>22, 23</sup>. However, most tracheostomy studies generalise to the greater paediatric population and include older children. Due to their smaller anatomy and medically complex indications, tracheostomies in infants are a high-risk procedure, and are associated with increased incidences of complications and mortality rates compared to adults<sup>13, 19, 24, 25</sup>. Despite this, there are no published Australian studies looking at the indications and outcomes of tracheostomy specifically in infants under 1 year of age.

The aim of this study is to identify the indications and associated outcomes of infant tracheostomies. We hypothesise that these have changed over time in Australia. Understanding these local trends will allow benchmarking against other international centres, enable better counselling of families, and increase quality of care for the vulnerable infant population.

#### Materials and methods

A retrospective review was conducted on all tracheostomy insertions between

January 1997 and November 2020 at Sydney Children's Hospital Randwick in
infants who were less than 1 year of age. Infants without a date of insertion,
indication for tracheostomy or had tracheostomy insertion at a different hospital
location were excluded in analyses. The primary outcome was indication for
tracheostomy. Secondary outcomes included length of stay (LOS), complications,
decannulation and mortality.

Patient data was collected using electronic medical records, or paper records if required. The data was securely stored on the University of New South Wales Research Electronic Data Capture (REDCap) server.

Tracheostomy indication was categorised into three groups: airway obstruction (AO), long-term ventilation (LTV), and pulmonary toilet (PT). If more than one indication was listed, the primary rationale behind tracheostomy insertion was recorded as the indication. Patients with neurological disorders were classified as either LTV or PT following individual review of their underlying condition and medical needs.

Length of stay (LOS) was classified into 4 groups: total hospital LOS, pretracheostomy hospital stay (number of days from admission until the tracheostomy was inserted), total intensive care unit (ICU) LOS and post-tracheostomy ICU stay.

Complications were defined as any deviation from the normal postoperative course that occurred with a tracheostomy in situ. As such, complications involving the expected adaptation to the insertion of a foreign object (e.g. granulation tissue) were excluded. Complications were classified into early (<7 days from tracheostomy

insertion), medium (between 7 days up to 3 months) and long-term (>3 months until decannulation).

Decannulation was defined as the purposeful or accidental removal of the tracheostomy tube that did not require re-insertion. Mortality outcomes including number of deaths, cause and age of death were also collected if available.

## Statistical analysis

Data analysis was conducted using IBM SPSS Statistics Version 26.0 (Armonk, NY). Descriptive statistics and frequency tables were used to characterise patients, their indications, and outcomes. Continuous variables were expressed using median (interquartile range [IQR]) and categorical variables were described as a number (percentage [%]) unless otherwise stated. Normality of distribution was determined using the Shapiro-Wilk Test.

To compare the changing indications and outcomes over the last two decades, patients were further classified according to the date of tracheostomy insertion: epoch 1 (1997–2008) and epoch 2 (2009–2020). The measure of association between categorical and continuous variables was determined using Fisher's exact test and Mann-Whitney U test or Kruskal-Wallis Test respectively. Binary logistic regression was undertaken to adjust for the effects of tracheostomy indication on mortality rates. A two-tailed p-value <0.05 was considered significant.

This study was approved by the Sydney Children's Hospital Network Human Research Ethics Committee (2020/ETH03107). A waiver of consent was obtained due to the retrospective nature of the study.

## Results and analysis

# **Demographics**

There were 77 infant tracheostomies performed in the 24-year period. After excluding five patients with missing or incomplete medical records, 72 patients were included in analysis. Of these tracheostomies, 40 (55.6%) and 32 (44.4%) patients were from epoch 1 and epoch 2 respectively.

Table I illustrates the demographics, clinical characteristics and comorbidities of patients undergoing a tracheostomy. Across both time periods, the median age at time of tracheostomy was 77.5 (28.5–196.3) days. The number of neonates aged less than 28 days in epoch 1 was significantly higher compared with epoch 2 (15 vs. 3, p=0.013). Sixty-seven (93.1%) patients had comorbidities, with developmental (54.2%) and gastrointestinal (45.8%) systems the most affected.

## Indications

The most common indication for tracheostomy insertion was AO (48/72, 66.7%) (Table II). Overall, there was a significant decline in the number of tracheostomies performed for AO between epoch 1 and epoch 2 (32 vs. 16, p=0.027). Craniofacial malformation was the most common principal diagnosis (20.8%), followed by vocal cord paralysis (11.1%). Craniofacial malformations decreased during this time-period (12 vs. 3, p=0.042).

LTV was the second most common indication for tracheostomy (20/72, 27.8%).

There was a significant increase in LTV as the primary indication for tracheostomy insertion in epoch 2 (7 vs. 13, p=0.034). Specifically, the number of patients with

chronic lung disease increased significantly between the two epochs (1 vs. 6, p=0.040). There was no statistically significant difference in the PT indication group between epoch 1 and 2 (1 vs. 3, p=0.310).

## Length of stay

Across both time periods, the total hospital LOS ranged from 5 to 822 days, as demonstrated in Table III. The median hospital LOS was 97 (53–205.5) days and patients spent a median time of 14 (1–34.8) days in hospital before a tracheostomy was inserted. The median total ICU LOS was 32.5 (16.3–105.8) days for this admission and the median time spent in ICU post-tracheostomy insertion was 22 (12–69) days.

There were no major differences in the comparison of all LOS subgroups between the two time periods. Patients requiring LTV had significantly higher total LOS (p<0.0001), pre-tracheostomy hospital LOS (p=0.023), ICU LOS (p<0.0001), post-tracheostomy ICU LOS (p<0.0001) than the AO group.

#### Complications

Complications were divided into early, medium and late-term (Table IV). Fourteen (19.4%) patients had early-term complications while 12 (16.7%) and 21 (29.2%) had medium and late-term complications respectively. 7 infants had multiple complications. The overall complication rate was 52.8%. The most common early, medium and late term complications were lung collapse (9.7%), tube obstruction (6.9%) and suprastomal collapse (15.3%) respectively.

There was a significant decline in early-term complications across the two epochs (12 v 2, p=0.016), particularly in early-term tube obstruction (6 vs. 0, p=0.033). There were no significant findings with total, medium and late-term complications.

#### Decannulation

The decannulation status of 71 patients were available (Table V). 43 (60.6%) patients were decannulated across both time periods, among which 26 (66.7%) were from the first epoch and 17 (53.1%) from the second epoch. There was no significant change in decannulation rates between the two time periods (p=0.330). While not significant, the number of patients living with a tracheostomy tended to be higher in epoch 2 in comparison with epoch 1 (6 vs. 11, p=0.093).

The median age of decannulation was 29 (15–43) months and the median time until decannulation was 24 (11–39) months. There was no significant change in the age at the time of decannulation (p=0.639) and time until decannulation (p=0.549) between epoch 1 and 2.

Post-decannulation, 29.2% (n=21) of patients had a tracheocutaneous fistula requiring intervention. Among these, 11 (27.5%) were from epoch 1, and 10 (31.3%) were from epoch 2. One (1.4%) patient suffered from a pneumothorax following decannulation. Complications that occurred post-operatively did not significantly differ over time.

## Mortality

A total of 12 (16.7%) patients died during this study period (Table VI). Among these patients, 11 died with a tracheostomy in situ. The remaining one patient died 8.5

years following decannulation due to an undetermined cause. Nine deaths were due to disease progression or complications and there were no deaths directly related to the tracheostomy. The causes of death for three patients were unable to be identified. Controlling for indication, there was no significant difference in mortality rates between the two epochs (20% vs. 12.5%, p=0.326, OR [95%CI] = 1.97[0.51–7.61]). There was also no significant difference in the median age of death between the two epochs (21 vs. 16.5 months, p=0.683).

#### **Discussion**

To our knowledge, this study is the first to characterise the changing profile of indications leading to tracheostomy and describe outcomes of tracheostomy practice in an Australian infant population.

Our study found a significant decrease in neonates who needed a tracheostomy inserted. The decline may be attributed to the advancements in neonatal resuscitation strategies with a shift in first-line airway management towards NIV and limiting use of invasive measures, such as a tracheostomy <sup>15, 16</sup>. As a result, a tracheostomy is considered following failure of NIV to support the neonate's ventilation requirements, meaning that these infants are receiving a tracheostomy later in their treatment course.

Most patients (93.1%) had other pre-existing comorbidities, with the most common being developmental delays (54.2%) followed by GIT-related conditions (45.8%). This was comparable to a study of 165 tracheostomised infants, where the most common comorbidities were also developmental (64.2%) and GIT-related (46.3%)<sup>26</sup>.

DeMauro et al. found that infants with a tracheostomy have a higher incidence of all in-hospital morbidities than those without<sup>27</sup>. These high comorbidities reflect the medically complex nature of infants requiring tracheostomy from a young age across multiple centres around the world.

Our findings showed AO as the most common indication for tracheostomy insertion, however this has notably decreased in the more recent epoch. Conversely, there was an upward trend in LTV as the primary indication. This shift is likely owing to changes in medical practice. Most importantly, the evolution of neonatal resuscitation techniques has led to the greater survival of premature infants requiring long-term airway management due to chronic lung disease<sup>28, 29</sup>. For these infants, a tracheostomy is only indicated when non-invasive ventilation is insufficient, or an extended duration of mechanical ventilation is required. Successful use of NIV reduces the need for intubation and its associated risks<sup>15, 16</sup> with a subsequent drop in acquired subglottic stenosis requiring bypass with a tracheostomy. Furthermore, in our centre, the use of nasopharyngeal airways (NPA) was adopted from 2009 (correlating with epoch 2) as a less invasive alternative to tracheostomy for upper AO. A NPA involves the placement of a modified endotracheal tube into the nasal passage and has been successfully used to avoid tracheostomy placement in children with upper AO, particularly craniofacial malformations<sup>30</sup>.

Our upward trend in LTV is concordant with more recent infant studies that have reported pulmonary disorders as the most common indication leading to tracheostomy insertion<sup>21, 31-33</sup>. However, there is heterogeneity in the published literature regarding indications for tracheostomy in infants<sup>19, 20, 34-37</sup>. This may be

attributed to differences across institutions and countries, namely the availability of medical care, ventilator access, local infrastructure and socioeconomic disparities.

The changing profile for tracheostomy indications has been reflected in paediatric papers comparing indications within the same institution over time<sup>38-41</sup>. Gergin et al. reported a substantial increase in cardiopulmonary disease leading to tracheostomy across three decades<sup>14</sup>. Our downward trend in upper AO corroborates with Sachdev et al., who analysed indications across an 18-year timeframe<sup>42</sup>. However, the inclusion of children greater than 1 year of age in these studies reduces the validity of comparison to the infant population.

Our median total LOS was 97 days, and the total ICU LOS was 32.5 days. These findings are comparable to Dursun et al., who observed a median LOS of 95 (11–327) days and ICU median LOS of 30 (1–115) days based on 30 infants (47%<1 year of age)<sup>43</sup>. However, the literature findings are diverse. A prospective multicentre North American study published significantly longer median hospital LOS of 226 (168–304) days while a Singaporean study of 105 paediatric patients (61%<1 year) conversely recorded a median LOS of 75 (39–138) days<sup>44</sup>. This significant variation in LOS may reflect different complex patient populations and incongruent paradigms of care between healthcare systems across different countries.

Despite changes in practice, there was no change in total hospital LOS over the two decades studied. Our study found LTV had significantly higher total LOS due to the higher degree of medical complexity in these patients compared to other indications. These findings are similar to a Canadian population of infants requiring respiratory support which documented considerably higher LOS with a median of 403 (77–1082) days and median ICU stay of 172 (0–659) days<sup>36</sup>.

The overall complication rate was 55.6% which was consistent with other infant tracheostomy studies, ranging from 18 to 81%<sup>27, 32, 44, 45</sup>. The large variation may be attributed to differing interpretations of complications. Like our study, many authors consider granulation tissue as a natural sequela of the surgical procedure as it is often asymptomatic<sup>46, 47</sup>. However, some studies have classified all granulation tissue as a complication<sup>32, 37</sup> while others only included it when intervention for airway compromise was required<sup>44, 48</sup>. The latter studies stated a higher rate of complications, demonstrating how different complications classifications contribute to variations.

The most feared early complications include emergency situations such as occlusion of the tracheostomy tube, accidental decannulation and lung collapse due to the high morbidity<sup>42</sup>. Our study reported a notable decrease in early term complications, particularly tube obstruction, which may correspond to improvements in intensive care management and small changes in surgical technique such as the use of maturation sutures.

In our cohort, decannulation rates have remained stable with an overall rate of 60.6%. This lies on the higher end of reported rates in literature, which varies from 17% to 69.3% in infants<sup>17, 20, 21, 33, 36, 43, 44</sup>. The variability can be attributed to inconsistencies in follow-up periods, with our findings correlating with other studies that did not adjust their time periods<sup>17, 20, 33, 44</sup>. Lower rates of decannulation were often observed in studies with defined follow-up periods<sup>36, 43</sup>.

As decannulation readiness is usually assessed based on the resolution or improvement of the tracheostomy indication, decannulation rates may be largely associated with the medical complexity of the individual patient<sup>44</sup> rather than

changes over time. Other possible confounding factors hindering decannulation success include feeding dysfunction, presence of comorbidities, caregiver readiness, resource availabilities and the timing of the procedure<sup>49, 50</sup>.

Our time to decannulation (mean $\pm$ standard deviation = 28.4 $\pm$ 20.8 months) was comparable with findings by Salley et al.  $(2.66\pm2.07 \text{ years})^{33}$  and Akangire et al.  $(33.88\pm19.3 \text{ months})^{35}$ . Institution-specific decannulation protocols add another contributing variable to the timing of decannulation.

The mortality rate in our study was 16.6% across both time periods. This lies within the published range of infant tracheostomy studies, which cite a mortality rate between 3.6% to 44% <sup>18, 21, 31, 37, 44</sup>. It is also comparable to paediatric tracheostomy mortality rates, which vary from 12% to 19% <sup>48, 51-53</sup>. The higher mortality rate in the infant group is a testament to the greater risk and complexity associated with infant tracheostomy in comparison to the overall paediatric population.

There were no tracheostomy-related deaths in our dataset, while the reported tracheostomy-related mortality rates in literature vary from 0% to 14% <sup>18, 32, 37, 54</sup>. There was no significant change observed in the mortality rate between the two time periods. Nine patients died from disease-related progression or complications, commonly from cardiac arrest (due to pulmonary hypertensive crisis or of unknown aetiology). This cause of death was consistent with other centres<sup>35</sup>.

Due to its retrospective design, study outcomes were restricted to the data documented in the pre-existing medical records. Complications and deaths that occurred in other centres or in the community were not available unless patients

were managed in hospital or self-reported these incidents in clinic visits, resulting in potential underreporting.

The study was limited by its small sample size obtained from a single paediatric tertiary institution. Tracheostomy indications could only be considered as a covariate for binary outcomes (i.e. mortality), but not other outcomes. This ultimately reduces the statistical power and generalisability of the results. However, our sample size was comparable with infant numbers in other single-centre tracheostomy studies<sup>17, 38, 40, 44, 47</sup>, merely reflecting the incidence of the procedure around the globe.

#### Conclusion

This study demonstrated a significant increase in LTV and decrease in AO as the primary indications leading to tracheostomy in an Australian infant population over time. Based on the findings of this study, knowledge of indications and outcomes will facilitate a more informed approach to clinical decision making as well as improve guidance and counselling of families on what to expect following a tracheostomy. This study ultimately provides an opportunity for improvement of patient care and a reduction of morbidity and mortality among a higher risk population.

**Summary Sheet** 

Advancements in neonatal resuscitation have changed tracheostomy

indications

Infant tracheostomy patients are a vulnerable yet under-reported population

group

Published literature on indications and outcomes of infant tracheostomy is

heterogeneous across different health systems and countries

• There is an increasing population of infants requiring tracheostomy due to

long-term ventilation over time. Complications, decannulation and mortality

rates have remained stable in infants requiring a tracheostomy

Australian tracheostomy outcomes in infants are comparable to other

international centres

**Funding** 

This research received no specific grant from any funding agency, commercial or

not-for-profit sectors.

**Declaration of Competing Interest** 

None.

16

#### References

- 1 Dal'Astra AP, Quirino AV, Caixêta JA, Avelino MA. Tracheostomy in childhood: review of the literature on complications and mortality over the last three decades. Braz J Otorhinolaryngol 2017;83:207-14
- 2 Bice T, Nelson JE, Carson SS. To Trach or Not to Trach: Uncertainty in the Care of the Chronically Critically III. Semin Respir Crit Care Med 2015;36:851-8
- 3 Hebert LM, Watson AC, Madrigal V, October TW. Discussing Benefits and Risks of Tracheostomy: What Physicians Actually Say. *Pediatr Crit Care Med* 2017;**18:**e592-e7
- 4 Zhu H, Das P, Roberson DW, Jang J, Skinner ML, Paine M, et al. Hospitalizations in children with preexisting tracheostomy: A national perspective. *Laryngoscope* 2015;**125**:462-8
- 5 Sakai M, Kou YF, Shah GB, Johnson RF. Tracheostomy demographics and outcomes among pediatric patients ages 18 years or younger-United States 2012. *Laryngoscope* 2019;**129**:1706-11
- 6 Flanagan F, Healy F. Tracheostomy decision making: From placement to decannulation. Semin Fetal Neonatal Med 2019;**24:**101037
- 7 Hopkins C, Whetstone S, Foster T, Blaney S, Morrison G. The impact of paediatric tracheostomy on both patient and parent. *Int J Pediatr Otorhinolaryngol* 2009;**73:**15-20
- 8 Nakarada-Kordic I, Patterson N, Wrapson J, Reay SD. A Systematic Review of Patient and Caregiver Experiences with a Tracheostomy. *Patient* 2018;**11:**175-91 9 Johnson RF, Brown A, Brooks R. The Family Impact of Having a Child with a Tracheostomy. *Laryngoscope* 2021;**131:**911-5

- 10 Süslü N, Ermutlu G, Akyol U. Pediatric tracheotomy: comparison of indications and complications between children and adults. *Turk J Pediatr* 2012;**54:**497

  11 Carter P, Benjamin B. Ten-year review of pediatric tracheotomy. *Ann Otol Rhinol Laryngol* 1983;**92:**398-400
- 12 Tucker JA, Silberman HD. Tracheotomy in pediatrics. *Ann Otol Rhinol Laryngol* 1972;**81:**818-24
- 13 Watters KF. Tracheostomy in Infants and Children. *Respir Care* 2017;**62**:799-825 14 Gergin O, Adil EA, Kawai K, Watters K, Moritz E, Rahbar R. Indications of pediatric tracheostomy over the last 30 years: Has anything changed? *Int J Pediatr Otorhinolaryngol* 2016;**87**:144-7
- 15 Ganu SS, Gautam A, Wilkins B, Egan J. Increase in use of non-invasive ventilation for infants with severe bronchiolitis is associated with decline in intubation rates over a decade. *Intensive Care Med* 2012;**38:**1177-83
- 16 Behnke J, Lemyre B, Czernik C, Zimmer K-P, Ehrhardt H, Waitz M. Non-Invasive Ventilation in Neonatology. *Dtsch Arztebl Int* 2019;**116:**177-83
- 17 Sidman JD, Jaguan A, Couser RJ. Tracheotomy and decannulation rates in a level 3 neonatal intensive care unit: a 12-year study. *Laryngoscope* 2006;**116**:136-9 18 Chen C-H, Chang J-H, Hsu C-H, Chiu N-C, Peng C-C, Jim W-T, et al. A 12-year-experience with tracheostomy for neonates and infants in northern Taiwan: Indications, hospital courses, and long-term outcomes. *Pediatr Neonatol* 2018;**59**:141-6
- 19 Lee JH, Smith PB, Quek MB, Laughon MM, Clark RH, Hornik CP. Risk Factors and In-Hospital Outcomes following Tracheostomy in Infants. *J Pediatr* 2016;**173**:39-44.e1

- 20 Cheng J, Lioy J, Sobol S. Effect of tracheostomy timing in premature infants. *Int J Pediatr Otorhinolaryngol* 2013;**77:**1873-6
- 21 Wood W, Wang CS, Mitchell RB, Shah GB, Johnson RF. A Longitudinal Analysis of Outcomes in Tracheostomy Placement Among Preterm Infants. *Laryngoscope* 2021;**131**:417-22
- 22 Muller RG, Mamidala MP, Smith SH, Smith A, Sheyn A. Incidence, Epidemiology, and Outcomes of Pediatric Tracheostomy in the United States from 2000 to 2012.

  Otolaryngol Head Neck Surg 2019;160:332-8
- 23 Ueno S, Fujino A, Morikawa Y, Iwanaka T, Kinoshita Y, Ozeki M, et al. Indications for tracheostomy in children with head and neck lymphatic malformation: analysis of a nationwide survey in Japan. *Surg Today* 2019;**49**:410-9
- 24 Watters K, O'Neill M, Zhu H, Graham RJ, Hall M, Berry J. Two-year mortality, complications, and healthcare use in children with medicaid following tracheostomy. *Laryngoscope* 2016;**126**:2611-7
- 25 Leavitt T, Brooks RL, Mitchell RB, Johnson RF, Chorney SR. Adolescent Tracheostomy for COVID-19 Respiratory Failure. *Ear Nose Throat J* 2024;**103**:NP22-24
- 26 Overman AE, Liu M, Kurachek SC, Shreve MR, Maynard RC, Mammel MC, et al. Tracheostomy for infants requiring prolonged mechanical ventilation: 10 years' experience. *Pediatrics* 2013;**131:**e1491-6
- 27 DeMauro SB, D'Agostino JA, Bann C, Bernbaum J, Gerdes M, Bell EF, et al. Developmental outcomes of very preterm infants with tracheostomies. *J Pediatr* 2014;**164**:1303-10.e2
- 28 Praud JP. Long-Term Non-invasive Ventilation in Children: Current Use, Indications, and Contraindications. *Front Pediatr* 2020;**8:**584334

- 29 Collaco JM, McGrath-Morrow SA. Respiratory Phenotypes for Preterm Infants, Children, and Adults: Bronchopulmonary Dysplasia and More. *Ann Am Thorac Soc* 2018;**15**:530-8
- 30 Parhizkar N, Saltzman B, Grote K, Starr J, Cunningham M, Perkins J, et al. Nasopharyngeal Airway for Management of Airway Obstruction in Infants with Micrognathia. *Cleft Palate Craniofac J* 2011;**48:**478-82
- 31 Han SM, Watters KF, Hong CR, Edwards EM, Knell J, Morrow KA, et al.

  Tracheostomy in Very Low Birth Weight Infants: A Prospective Multicenter Study.

  Pediatrics 2020;145:e20192371
- 32 Pereira KD, Shaigany K, Zur KB, Jenks CM, Preciado DA, Hamdi O, et al.

  Tracheostomy in the Extremely Premature Neonate: A Multi-Institutional Study.

  Otolaryngol Head Neck Surg 2020;162:559-65
- 33 Salley JR, Kou YF, Shah GB, Johnson RF. Comparing Long-Term Outcomes in Tracheostomy Placed in the First Year of Life. *Laryngoscope* 2021;**131**:2115-20 34 Saadia A, Prasad G. Neonatal tracheostomy issues and solutions. *J Neonatal Surg* 2015;**4:**13
- 35 Akangire G, Taylor JB, McAnany S, Noel-MacDonnell J, Lachica C, Sampath V, et al. Respiratory, growth, and survival outcomes of infants with tracheostomy and ventilator dependence. *Pediatr Res* 2021;**90**:381-9
- 36 Bergeron Gallant K, Sauthier M, Kawaguchi A, Essouri S, Quintal MC, Emeriaud G, et al. Tracheostomy, respiratory support, and developmental outcomes in neonates with severe lung diseases: Retrospective study in one center. *Arch Pediatr* 2020;**27**:270-4

- 37 Cardoso L, Ribeiro JC, Neves J, Cruz M, Silva L. Tracheotomy decannulation in children under one year of age. *Arch Head Neck Surg* 2018;47:e0928

  38 Douglas CM, Poole-Cowley J, Morrissey S, Kubba H, Clement WA, Wynne D. Paediatric tracheostomy—An 11 year experience at a Scottish paediatric tertiary referral centre. *Int J Pediatr Otorhinolaryngol* 2015;79:1673-6

  39 Jain MK, Patnaik S, Sahoo B, Mishra R, Behera JR. Tracheostomy in Pediatric Intensive Care Unit: Experience from Eastern India. *Indian J Pediatr* 2021;88:445-9

  40 Roberts J, Powell J, Begbie J, Siou G, McLarnon C, Welch A, et al. Pediatric
- tracheostomy: A large single-center experience. *Laryngoscope* 2020;**130**:E375-E80 41 Mizuno K, Takeuchi M, Kishimoto Y, Kawakami K, Omori K. Indications and outcomes of paediatric tracheotomy: a descriptive study using a Japanese claims database. *BMJ Open* 2019;**9**:e031816
- 42 Sachdev A, Chaudhari ND, Singh BP, Sharma N, Gupta D, Gupta N, et al.

  Tracheostomy in pediatric intensive care unit—two decades of experience. *Indian J Crit Care Med* 2021;**25**:803-11
- 43 Dursun O, Ozel D. Early and long-term outcome after tracheostomy in children.

  Pediatr Int 2011;53:202-6
- 44 Chia AZH, Ng ZM, Pang YX, Ang AHC, Chow CCT, Teoh OH, et al. Epidemiology of Pediatric Tracheostomy and Risk Factors for Poor Outcomes: An 11-Year Single-Center Experience. *Otolaryngol Head Neck Surg* 2020;**162**:121-8
- 45 Pereira KD, MacGregor AR, McDuffie CM, Mitchell RB. Tracheostomy in Preterm Infants: Current Trends. *Arch Otolaryngol Head Neck Surg* 2003;**129**:1268-71 46 Kremer B, Botos-Kremer AI, Eckel HE, Schlöndorff G. Indications, complications, and surgical techniques for pediatric tracheostomies—An update. *J Pediatr Surg* 2002;**37**:1556-62

- 47 Ogilvie LN, Kozak JK, Chiu S, Adderley RJ, Kozak FK. Changes in pediatric tracheostomy 1982–2011: a Canadian tertiary children's hospital review. *J Pediatr Surg* 2014;**49:**1549-53
- 48 Özmen S, Özmen ÖA, Ünal ÖF. Pediatric tracheotomies: A 37-year experience in 282 children. *Int J Pediatr Otorhinolaryngol* 2009;**73:**959-61
- 49 Bandyopadhyay A, Cristea AI, Davis SD, Ackerman VL, Slaven JE, Jalou HE, et al. Retrospective Analysis of Factors Leading to Pediatric Tracheostomy

  Decannulation Failure. A Single-Institution Experience. *Ann Am Thorac Soc*2017;**14:**70-5
- 50 Falla PI, Westhoff JH, Bosch N, Federspil PA. Factors influencing time-dependent decannulation after pediatric tracheostomy according to the Kaplan–Meier method. *Eur Arch Otorhinolaryngol* 2020;**277**:1139-47
- 51 Groenendijk I, Booth J, van Dijk M, Argent A, Zampoli M. Paediatric tracheostomy and ventilation home care with challenging socioeconomic circumstances in South Africa. *Int J Pediatr Otorhinolaryngol* 2016;**84**:161-5
- 52 Mahadevan M, Barber C, Salkeld L, Douglas G, Mills N. Pediatric tracheotomy: 17 year review. *Int J Pediatr Otorhinolaryngol* 2007;**71:**1829-35
- 53 Al-Samri M, Mitchell I, Drummond DS, Bjornson C. Tracheostomy in children: a population-based experience over 17 years. *Pediatr Pulmonol* 2010;**45**:487-93 54 Isaiah A, Moyer K, Pereira KD. Current Trends in Neonatal Tracheostomy. *JAMA Otolaryngol Head Neck Surg* 2016;**142**:738-42

# **Tables**

**TABLE I – Patient Demographics and Comorbidities** 

	Epoch 1	Epoch 2	Total	OR (95% CI)	p value
Number of patients (n)	40 (55.6)	32 (44.4)	72 (100.0)	N/A*	N/A*
Age at time of tracheostomy (d)	74 (17.5 – 193.5)	94.5 (38.5 – 203)	77.5 (28.5 – 196.3)	N/A*	0.133
Neonates**	15 (35.7)	3 (9.4)	18 (24.3)	5.37 (1.40 – 20.63)	0.013
Male sex	26 (63.4)	19 (59.4)	45 (61.6)	0.84 (0.33 – 2.18)	0.810
Aboriginal/Torres Strait Islander	2 (5.0)	2 (6.3)	4 (5.6)	0.79 (0.11 – 5.94)	1.000
Birth weight (g)	2700 (2135 – 3485)	2250 (1160 – 2960)	2520 (1850 – 3274)	N/A*	0.092
Gestational age (w)	37 (32 – 39)	36 (33.8 – 39)	37 (33.5 – 39)	N/A*	0.766
Comorbidities	35 (87.5)	32 (100)	67 (93.1)	0.88 (0.78 – 0.98)	0.061
Developmental	20 (50.0)	19 (59.4)	39 (54.2)	1.46 (0.57 – 3.74)	0.481

Gastrointestinal	19 (47.5)	14 (43.8)	33 (45.8)	0.86 (0.34 – 2.19)	0.814
Neurological	14 (35.0)	15 (46.9)	29 (40.3)	1.64 (0.63 – 4.24)	0.342
Musculoskeletal	15 (37.5)	12 (37.5)	27 (37.5)	1.00 (0.38 – 2.61)	1.000
Respiratory	14 (35.0)	12 (37.5)	26 (36.1)	1.11 (0.42 – 2.93)	1.000
Cardiac	14 (35.0)	12 (37.5)	26 (36.1)	1.11 (0.42 – 2.93)	1.000
Otolaryngology	12 (32.5)	8 (25.0)	21 (29.2)	0.69 (0.25 – 1.96)	0.604
Ocular	9 (22.5)	11 (34.3)	20 (27.8)	1.80 (0.64 – 5.11)	0.299
Renal	4 (10)	4 (12.5)	8 (11.1)	1.29 (0.30 – 5.60)	1.000
Other	7 (17.5)	11 (34.3)	18 (25.0)	2.47 (0.83 – 7.38)	0.111

Abbreviations: CI = confidence interval; d = days; g = grams; IQR = interquartile range; n = number of patients; N/A = not available; OR = odds ratio; w = weeks

For incomplete data, proportions were calculated as percentages/means of the available data, rather the entire cohort Data is expressed as median (IQR) or number (%) unless otherwise specified

<sup>\*</sup> Analysis not applicable or unable to be obtained due to cell numbers

<sup>\*\*</sup> Neonates were defined as patients who had a tracheostomy inserted at  $\leq$  28 days

Table II – Indications for Tracheostomy

Primary Indication and Diagnosis	Epoch 1 (n = 40)	Epoch 2 (n = 32)	Total (n = 72)	OR (95% CI)	p value
Airway obstruction	32 (80.0)	16 (50.0)	48 (66.7)	0.31 (0.12 – 0.84)	0.027
Craniofacial malformations <sup>a</sup>	12 (30.0)	3 (9.4)	15 (20.8)	0.24 (0.06 – 0.95)	0.042
Vocal cord paralysis	3 (7.5)	5 (15.6)	8 (11.1)	2.28 (0.50 – 10.39)	0.453
Subglottic stenosis	6 (15.0)	1 (3.1)	7 (9.7)	0.18 (0.02 – 1.61)	0.123
Syndrome resulting in airway obstruction <sup>b</sup>	3 (7.5)	3 (9.4)	6 (8.3)	1.28 (0.24 – 6.80)	1.000
Laryngomalacia	5 (12.5)	0 (0.0)	5 (6.9)	N/A*	0.061
Tracheomalacia	4 (10.0)	1 (3.1)	5 (6.9)	0.29 (0.03 – 2.74)	0.373
Neoplasm resulting in airway obstruction	2 (5.0)	2 (6.3)	4 (5.6)	1.27 (0.17 – 9.53)	1.000
Cystic hygroma	2 (5.0)	1 (3.1)	3 (4.2)	0.61 (0.05 – 7.08)	1.000
Obstructive sleep apnoea	0 (0.0)	1 (3.1)	1 (1.4)	N/A*	0.444
Long-term ventilation	7 (17.5)	13 (40.6)	20 (27.8)	3.42 (1.17 – 10.03)	0.034
Chronic lung disease	1 (2.5)	6 (18.8)	7 (9.7)	9.00 (1.02 – 79.17)	0.040

Chronic diaphragmatic hernia	1 (2.5)	1 (3.1)	2 (2.8)	1.26 (0.08 – 20.93)	1.000
Infections	3 (7.5)	0 (0.0)	3 (4.2)	N/A*	0.249
Neoplasm requiring LTV	0 (0.0)	1 (3.1)	1 (1.4)	N/A*	0.444
Chromosomal abnormality	0 (0.0)	2 (6.3)	2 (2.8)	N/A*	0.194
Trauma	1 (2.5)	0 (0.0)	1 (1.4)	N/A*	1.000
Syndrome requiring LTV	0 (0.0)	1 (3.1)	1 (1.4)	N/A*	0.444
Congenital hypoventilation syndrome	0 (0.0)	1 (3.1)	1 (1.4)	N/A*	0.444
Bulbar dysfunction requiring LTV	0 (0.0)	1 (3.1)	1 (1.4)	N/A*	0.444
Cardiac conditions	1 (2.5)	0 (0.0)	1 (1.4)	N/A*	1.000
Pulmonary toilet	1 (2.5)	3 (9.4)	4 (5.6)	4.24 (0.42 – 42.84)	0.310
Neurological conditions	1 (2.5)	3 (9.4)	4 (5.6)	4.24 (0.42 – 42.84)	0.310

Abbreviations: CI = confidence interval; LTV = long-term ventilation; n = number of patients; N/A = not available; OR = odds ratio

<sup>&</sup>lt;sup>a</sup> Patients with syndromes involving craniofacial malformations were classified under 'craniofacial malformations'

<sup>&</sup>lt;sup>b</sup> Patients with syndromes not involving craniofacial malformations were classified as 'syndrome resulting in airway obstruction' if airway obstruction was indicated

<sup>\*</sup> Analysis not applicable or unable to be obtained due to cell numbers

Patients classified under the same primary diagnosis (e.g. neoplasm) may have different indications for tracheostomy.

For patients with multiple diagnosis, the principal diagnosis was recorded for the purposes of the study.

Data expressed as number (%)

Table III - Length of stay

	Epoch 1 (n = 40)	Epoch 2 (n = 32)	Total (n = 72)	Total Range	p value
Total hospital LOS (d) <sup>a</sup>	97 (49.8 – 212)	97 (57.8 – 201)	97 (53 – 205.5)	5 – 822	0.700
AO	67 (44.5 – 110.5)	59.5 (43.5 – 76.8)	63.5 (44.5 – 100.8)	5 – 357	0.341
LTV	247 (221 – 441)	208 (151.5 – 295)	232.5 (172.5 – 308.5)	64 – 822	0.115
PT	123 (123 – 123)	107 (65 – )*	115 (75.5 – 161.3)	65 – 174	1.000
Pre-tracheostomy hospital LOS (d) <sup>b</sup>	10 (1 – 30.75)	21.5 (1.3 – 39)	14 (1 – 34.8)	0 – 201	0.360
AO	5.5 (1 – 17.8)	10 (0.25 – 42.3)	8.5 (1 – 18.8)	0 – 159	0.516
LTV	33 (19 – 97)	23 (4.5 – 46.5)	28.5 (9.75 – 51.8)	0 – 201	0.351
PT	72 (72 – 72)	27 (25 – )*	28.5 (25.5 – 61.5)	25 – 72	0.500
Total ICU LOS (d) <sup>c</sup>	26.5 (13 – 84.5)	36.5 (21.3 – 120.5)	32.5 (16.3 – 105.8)	6 – 605	0.172
AO	18.5 (12 – 49.75)	22 (17 – 33.8)	20 (13 – 39.5)	5 – 310	0.562
LTV	206 (92 – 256)	131 (74 – 233)	144 (94.5 – 245.5)	16 – 605	0.536

PT	41 (41 – 41)	32 (25 – )*	36.5 (26.8 – 47)	25 – 49	1.000
Post-tracheostomy ICU LOS (d) <sup>d</sup>	16.5 (12 – 58.3)	26 (13.5 – 104)	22 (12 – 69)	5 – 572	0.257
AO	12.5 (10.3 – 37)	16 (12.3 – 22.8)	13 (11.3 – 29.8)	5 – 275	0.669
LTV	161 (73 – 247)	118 (48.5 – 183)	121.5 (65 – 193)	8 – 572	0.393
PT	28 (28 – 28)	29 (22 – )*	28.5 (23.5 – 29.8)	22 – 300	1.000

Abbreviations:  $AO = airway \ obstruction; \ d = days; \ ICU = intensive \ care \ unit; \ IQR = interquartile \ range; \ LOS = length \ of \ stay; \ LTV = long-term \ ventilation; \ n = number \ of \ patients; \ PT = pulmonary \ toilet$ 

Data expressed as median (IQR)

<sup>&</sup>lt;sup>a</sup> Total hospital LOS: the total number of days in hospital during the admission at which the tracheostomy was inserted

<sup>&</sup>lt;sup>b</sup> Pre-tracheostomy hospital LOS: the number of days from the date of hospital admission until the date at which the tracheostomy was inserted

<sup>&</sup>lt;sup>c</sup> Total ICU LOS: the number of days in the ICU during the admission at which the tracheostomy was inserted

<sup>&</sup>lt;sup>d</sup> Post-tracheostomy ICU LOS: the number of days spent in the ICU from the date of tracheostomy insertion until ICU discharge

<sup>\*</sup> Analysis not applicable or unable to be obtained due to cell numbers

Table IV - Complications

	Epoch 1 (n = 40)	Epoch 2 (n = 32)	Total (n = 72)	OR (95% CI)	p value
Total	23 (57.5)	15 (46.9)	38 (52.8)	0.65 (0.26 – 1.66)	0.477
Early-term <sup>a</sup>	12 (30.0)	2 (6.3)	14 (19.4)	6.43 (1.32 – 31.31)	0.016
Lung collapse	5 (12.5)	2 (6.3)	7 (9.7)	0.47 (0.08 – 2.58)	0.451
Tube obstruction	6 (15)	0 (0.0)	6 (8.3)	N/A*	0.033
Bleeding	3 (7.5)	0 (0.0)	3 (4.2)	N/A*	0.074
Infection	2 (5.0)	0 (0.0)	2 (2.8)	N/A*	0.499
Accidental decannulation	1 (2.5)	0 (0.0)	1 (1.4)	N/A*	0.421
Pleural effusion	1 (2.5)	0 (0.0)	1 (1.4)	N/A*	1.000
Medium-term <sup>b</sup>	7 (17.5)	5 (15.6)	12 (16.7)	1.15 (0.33 – 4.02)	1.000
Tube obstruction	4 (10.0)	1 (3.1)	5 (6.9)	0.29 (0.03 – 2.74)	0.373
Infections	1 (2.5)	2 (6.3)	3 (4.2)	2.60 (0.23 – 30.05)	0.581
Bleeding	1 (2.5)	1 (3.1)	2 (2.8)	1.26 (0.08 – 20.93)	1.000
Lung collapse	1 (2.5)	1 (3.1)	2 (2.8)	1.26 (0.08 – 20.93)	1.000

Accidental decannulation	1 (2.5)	0 (0.0)	1 (1.4)	N/A*	1.000
Late-term <sup>c</sup>	12 (30.0)	9 (28.1)	21 (29.2)	1.10 (0.39 – 3.05)	1.000
Suprastomal collapse	8 (20.0)	3 (9.4)	11 (15.3)	0.41 (0.10 – 1.71)	0.325
Accidental decannulation	2 (5.0)	3 (9.4)	5 (6.9)	1.97 (0.31 – 12.54)	0.650
Tube obstruction	4 (10.0)	0 (0.0)	4 (5.6)	N/A*	0.124
Bleeding	1 (2.5)	2 (6.3)	3 (4.2)	2.60 (0.23 – 30.05)	0.581
Infection	0 (0.0)	3 (9.4)	3 (4.2)	N/A*	0.083
Stoma contraction	0 (0.0)	1 (3.1)	1 (1.4)	N/A*	0.444

Abbreviations: CI = confidence interval; n = number of patients; N/A = not available; OR = odds ratio

<sup>&</sup>lt;sup>a</sup> Early-term: < 7 days from date of tracheostomy insertion; <sup>b</sup> Medium-term: 7 days to 3 months from date of tracheostomy insertion; <sup>c</sup> Long-term: 3 months to date of decannulation

<sup>\*</sup> Analysis not applicable or unable to be obtained due to cell numbers

**Table V – Decannulation** 

	Epoch 1 (n = 39)	Epoch 2 (n = 32)	Total (n = 71)	OR (95% CI)	<i>p</i> value
Decannulated	26 (66.7)	17 (53.1)	43 (60.6)	0.57 (0.22 – 1.48)	0.330
Living with tracheostomy	6 (15.4)	11 (34.4)	17 (23.9)	2.88 (0.93 – 8.97)	0.093
Died with tracheostomy	7 (17.9)	4 (36.4)	11 (15.5)	0.65 (0.17 – 2.47)	0.742
Age of decannulation (m) <sup>a</sup>	28 (16 – 47.25)	29 (11 – 37.5)	29 (15 – 43)	N/A*	0.639
Time until decannulation (m) <sup>b</sup>	24 (14.5 – 47)	24 (5.5 – 33.5)	24 (11 – 39)	N/A*	0.549
Complications post-decannulation	11 (27.5)	10 (31.3)	21 (29.2)	1.20 (0.43 – 3.32)	0.728
Transcutaneous fistula	11 (27.5)	10 (31.3)	21 (29.2)	1.20 (0.43 – 3.32)	0.797
Pneumothorax	0 (0.0)	1 (3.1)	1 (1.4)	N/A*	0.444

Abbreviations: CI = confidence interval; m = months; n = number of patients; N/A = not available; OR = odds ratio,

<sup>&</sup>lt;sup>a</sup> Age of decannulation refers to the age of the patient at the time of decannulation

<sup>&</sup>lt;sup>b</sup> Time until decannulation refers to the length of time between when the tracheostomy was inserted and when it was removed

<sup>\*</sup> Analysis not applicable or unable to be obtained due to cell numbers

One patient had both a pneumothorax and transcutaneous fistula post-decannulation

Data is expressed as median (IQR) or number (%) unless otherwise specified

Table VI – Mortality

	Tracheostomy	Comorbidities	Age at Death (m)	Cause of Death
	Indication			
Epoch 1				
Patient 1	AO	Syndrome, developmental, neurological,	119	N/A
		musculoskeletal, ocular		
Patient 2	AO	Syndrome, developmental	60	N/A
Patient 3	AO	Undiagnosed syndrome	0	Syndrome progression
Patient 4	LTV	Respiratory, cardiac	9	Sepsis
Patient 5	AO	Respiratory, cardiac, musculoskeletal, GIT	8	Cardiac arrest of no clear
				cause
Patient 6	LTV	Respiratory, cardiac, ENT	33	Chestinfection
Patient 7	PT	Neurological, ocular, GIT	69	N/A
Patient 8	LTV	Cardiac, GIT, ENT	8	Cardiac arrest due to
				pulmonary hypertensive crisis

Patient 9	LTV	Syndrome, developmental, cardiac,	16	Cardiac arrest of no clear
		neurological, ocular, ENT		cause
Patient 10	LTV	Undiagnosed syndrome, respiratory, renal	8	Respiratory failure
Patient 11	LTV	Respiratory, developmental, neurological,	17	Mechanical ventilation
		GIT, ENT		withdrawn
Patient 12	LTV	Syndrome, respiratory, developmental,	17	Palliative care
		cardiac, neurological, musculoskeletal,		
		cardiac, neurological, musculoskeletal, ocular		

Abbreviations:  $AO = airway \ obstruction; \ LTV = long-term \ ventilation; \ m = months; \ N/A = not \ available; \ PT = pulmonary \ toilet$ 

# **Summary Sheet**

- Advancements in neonatal resuscitation have changed tracheostomy indications
- Infant tracheostomy patients are a vulnerable yet under-reported population group
- Published literature on indications and outcomes of infant tracheostomy is heterogeneous across different health systems and countries
- There is an increasing population of infants requiring tracheostomy due to long-term ventilation over time. Complications, decannulation and mortality rates have remained stable in infants requiring a tracheostomy
- Australian tracheostomy outcomes in infants are comparable to other international centres